Zydus Lifesciences Ltd. announced on Wednesday that the company has received final approval from the United States Food and Drug Administration to market Sacubitril and Valsartan tablets.
The Sacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation. The pharmaceutical firm will manufacture the drug at the group’s formulation manufacturing facility in Moraiya, Ahmedabad, according to an exchange filing.
The company now has 399 approvals and over 460 abbreviated new drug application approvals from the FDA since the commencement of the filing process.